Alliance Pharma PLC

Block Listing Six Monthly Return

RNS Number : 0142E
Alliance Pharma PLC
02 July 2021


For immediate release

2 July 2021





("Alliance" or the "Company")


Block Listing Six Monthly Return


Name of applicant:


Names of schemes:

a)  The Alliance Pharma plc Approved Share Option Plan 2005

b)  The Alliance Pharma plc Share Option Plan 2006

c)  The Alliance Pharma plc Company Share Option Plan 2015

Period of return:


28 December 2020


28 June 2021

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a)  293,372

b)  5,266,622

c)  13,265,746

Plus:   The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a)  Nil

b)  Nil

c)  Nil

Less:   Number of securities issued/allotted under schemes during period:

a)  258,052

b) 317,909

c)  1,816,189


Equals:   Balance under schemes not yet issued/allotted at end of period:

d)  35,320

e)  4,948,713

f)  11,449,557


Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166


For further information:


Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer


+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele

Corporate Broking: James Black


Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

Corporate Broking: Patrick Robb


About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.